Afzelin ameliorates D-galactosamine and lipopolysaccharide-induced fulminant hepatic failure by modulating mitochondrial quality control and dynamics.

MLA

Lee, Sang-Bin, et al. “Afzelin Ameliorates D-Galactosamine and Lipopolysaccharide-Induced Fulminant Hepatic Failure by Modulating Mitochondrial Quality Control and Dynamics.” British Journal of Pharmacology, vol. 174, no. 2, Jan. 2017, pp. 195–209. EBSCOhost, https://doi.org/10.1111/bph.13669.

APA

Lee, S.-B., Kang, J.-W., Kim, S.-J., Ahn, J., Kim, J., & Lee, S.-M. (2017). Afzelin ameliorates D-galactosamine and lipopolysaccharide-induced fulminant hepatic failure by modulating mitochondrial quality control and dynamics. British Journal of Pharmacology, 174(2), 195–209. https://doi.org/10.1111/bph.13669

Chicago

Lee, Sang-Bin, Jung-Woo Kang, So-Jin Kim, Jongmin Ahn, Jinwoong Kim, and Sun-Mee Lee. 2017. “Afzelin Ameliorates D-Galactosamine and Lipopolysaccharide-Induced Fulminant Hepatic Failure by Modulating Mitochondrial Quality Control and Dynamics.” British Journal of Pharmacology 174 (2): 195–209. doi:10.1111/bph.13669.